ANDAs For Narrow Therapeutic Index Drugs May Need Crossover Studies
Executive Summary
FDA’s challenges in creating a more specific definition of narrow therapeutic index drugs were on clear display at the most recent advisory committee meeting on the topic: There’s wide support for the project, but equally broad concern that it needs to be more carefully tailored.